Testis cancer: some problems still remain unsolved

Testis cancer: some problems still remain unsolved World J Urol (2017) 35:1159–1160 DOI 10.1007/s00345-017-2041-5 EDITORIAL 1 2 Peter Albers · Carsten Bokemeyer Received: 18 April 2017 / Accepted: 19 April 2017 / Published online: 16 May 2017 © Springer-Verlag Berlin Heidelberg 2017 In spite of an increasing incidence in most of the Northern of patients that cannot undergo complete resections [3]. industrialized countries in Europe germ cell cancer remains Salvage high-dose chemotherapy regimens are currently a rare disease. Diagnostic and management strategies have standard of care to treat recurrent disease. Exact classifica - been published numerously, but still there remain prob- tion of patients using the Lorch–Beyer classification system lems to be solved. Oldenburg and Dieckmann balanced the for recurrences and a large body of experience is necessary debate of pros and cons of a contralateral biopsy. Bottom to achieve optimal results with these potentially toxic regi- line is that a contralateral biopsy is the only way to early mens [4]. More and more data demand this salvage treat- detect cancer within the “testicular dysgenesis syndrome” ment to be regionalized in centers with high experience. which has been molecularly identified over the last years This exactly is true as well for the second component of by http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png World Journal of Urology Springer Journals

Testis cancer: some problems still remain unsolved

Loading next page...
 
/lp/springer_journal/testis-cancer-some-problems-still-remain-unsolved-1V7Copajj3
Publisher
Springer Berlin Heidelberg
Copyright
Copyright © 2017 by Springer-Verlag Berlin Heidelberg
Subject
Medicine & Public Health; Urology; Nephrology; Oncology
ISSN
0724-4983
eISSN
1433-8726
D.O.I.
10.1007/s00345-017-2041-5
Publisher site
See Article on Publisher Site

Abstract

World J Urol (2017) 35:1159–1160 DOI 10.1007/s00345-017-2041-5 EDITORIAL 1 2 Peter Albers · Carsten Bokemeyer Received: 18 April 2017 / Accepted: 19 April 2017 / Published online: 16 May 2017 © Springer-Verlag Berlin Heidelberg 2017 In spite of an increasing incidence in most of the Northern of patients that cannot undergo complete resections [3]. industrialized countries in Europe germ cell cancer remains Salvage high-dose chemotherapy regimens are currently a rare disease. Diagnostic and management strategies have standard of care to treat recurrent disease. Exact classifica - been published numerously, but still there remain prob- tion of patients using the Lorch–Beyer classification system lems to be solved. Oldenburg and Dieckmann balanced the for recurrences and a large body of experience is necessary debate of pros and cons of a contralateral biopsy. Bottom to achieve optimal results with these potentially toxic regi- line is that a contralateral biopsy is the only way to early mens [4]. More and more data demand this salvage treat- detect cancer within the “testicular dysgenesis syndrome” ment to be regionalized in centers with high experience. which has been molecularly identified over the last years This exactly is true as well for the second component of by

Journal

World Journal of UrologySpringer Journals

Published: May 16, 2017

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off